51. Vaccines and nephrotic syndrome: efficacy and safety
- Author
-
Angeletti, Andrea, Lugani, Francesca, La Porta, Edoardo, Verrina, Enrico, Caridi, Gianluca, and Ghiggeri, Gian Marco
- Subjects
Drugs -- Adverse and side effects ,Nephrotic syndrome -- Risk factors ,Communicable diseases in children -- Prevention ,Vaccines -- Complications and side effects ,Pediatric research ,Health - Abstract
Vaccines represent the most important medical evolution in the last two centuries allowing prevention and formally eradication of a wide number of infectious diseases. Safety and effectiveness are main issues that still require an open discussion. A few clinical reports described a critical temporal relationship between vaccination and acute nephrotic syndrome, indirectly suggesting an association. For this review, the literature was reviewed to identify articles reporting associations of nephrotic syndrome with vaccines against a vast array of infectious diseases (including bacteria, virus and Sars-Cov-2). As specific aims, we evaluated effectiveness and safety in terms of occurrence of either 'de novo' nephrotic syndrome in health subjects or 'relapse' in those already affected by the disease. In total, 377 articles were found; 166 duplicates and 71 non-full text, animal studies or non-English language were removed. After excluding another 50 articles not containing relevant data on generic side effects or on relapses or new onset nephrotic syndrome, 90 articles met the search criteria. Overall, studies reported the effect of vaccines in 1015 patients, plus 4 nationwide epidemiologic investigations. Limited experience on vaccination of NS patients with measles, mumps, and rubella live attenuated vaccines does not allow any definitive conclusion on their safeness. VZV has been administered more frequently without side effects. Vaccines utilizing virus inactivated, recombinant, and toxoid can be utilized without risks in NS. Vaccines for influenza reduce the risk of infections during the pandemic and are associated with reduced risk of relapse of NS typically induced by the infection. Vaccines for SARS-CoV-2 (all kinds) offer a concrete approach to reduce the pandemic. 'De novo' NS or recurrence are very rare and respond to common therapies., Author(s): Andrea Angeletti [sup.1] , Francesca Lugani [sup.1] , Edoardo La Porta [sup.1] , Enrico Verrina [sup.1] , Gianluca Caridi [sup.1] , Gian Marco Ghiggeri [sup.1] Author Affiliations: (1) grid.419504.d, [...]
- Published
- 2023
- Full Text
- View/download PDF